- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05770635
Polyvinyl Alcohol Embolization Microspheres
A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of Polyvinyl Alcohol Embolization Microspheres for Transarterial Chemoembolization of Primary Liver Cancer
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201615
- Shanghai Huihe Healthcare Tecnology Co.,Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age≥18 years old; age ≤85 years old; regardless of gender
- Patients with CNLC Ib, IIa, IIb, IIIa who need transarterial chemoembolization (TACE) therapy and are not suitable for or refuse surgical resection, liver transplantation, and ablation, and patients with stage IIIb primary liver cancer who are expected to benefit from TACE therapy to control the growth of intrahepatic tumors;
- Child-Pugh A or B (less than 10 points);
- performance status (PS) score of ECOG 0~2;
- The patient had at least one measurable tumor lesion without embolization (maximum diameter of the target lesion ≤10cm);
- Those who agree to participate in the clinical trial and voluntarily sign the informed consent;
Exclusion Criteria:
- Patients whose target lesions had received embolization therapy, whose target lesions had received other local treatments besides TACE (including but not limited to surgery, radiotherapy, hepatic arterial perfusion, radiofrequency ablation, cryoablation or percutaneous ethanol injection) within 1 month, or who had received first TACE therapy for target lesions combined with ablation/radiotherapy after inclusion;
- The proportion of tumor in total liver volume was ≥70%;
- Patients with distant extensive metastasis or other malignant tumors;
- The expected survival time is less than 3 months;
- Cachexia or multiple organ failure;
- Severe liver dysfunction (Child-Pugh grade C), including jaundice, hepatic encephalopathy, refractory ascites, or hepatorenal syndrome;
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal or >250U/L, and ≥2 times the upper limit of normal after 1 week of liver protection and antiviral treatment;
- Renal dysfunction: patients with serum creatinine > 2mg/dL;
- Blood leukocytes and platelets decreased significantly, leukocytes < 3.0×109/L, platelets < 50×109/L (except patients with hyperplenism and chemotherapy myelosuppression);
- Bleeding and thrombotic tendency: patients with known hereditary or acquired bleeding and thrombotic tendency (e.g., hemophiliacs, uncorrectable coagulation disorders, thrombocytopenia, hyperplenism, etc.), active peptic ulcer or gastrointestinal bleeding within 30 days; Arteriovenous thrombosis occurred in the past 6 months (until enrollment);
- Patients with active hepatitis or severe infection who cannot be treated with TACE simultaneously;
- Patients with complete obstruction of the main portal vein and unable to restore portal blood flow through compensatory collateral branches of the portal vein;
- The target focal blood supply arteries cannot be treated with TACE or have the risk of embolization (vascular access endangers normal areas, arteriovenous fistula, portal fistula, etc.);
- Subjects who predicted that the target lesion would require more than three TAces; Uncontrolled diabetes mellitus; 15.
16. People with known severe allergy to contrast agents, iodine contrast agents or embolic materials; 17. Pregnant/lactating women, or those who plan to give birth; 18. Patients who are participating in clinical trials of other drugs or devices and have not been in the group or have been in the group for less than 1 month; 19. Persons without the ability to make independent decisions or with mental illness; 20. Other patients deemed unsuitable for this clinical trial by the investigator;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug
The experimental group received chemotherapy drug + polyvinyl alcohol embolized microspheres (Huihe Medical) for target lesion TACE (Trans-Arterial Chemoembolization)treatment.Experimental group and control group were selected to use iodide oil according to the condition of subjects.
|
chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition
|
Other: Embosphere and chemotherapy drug
|
chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) 1 month after the last TACE -mRECIST evaluation
Time Frame: 1 month after the last TACE -mRECIST evaluation
|
Target lesions of subjects were treated with TACE for 1-3 times as needed, and the last evaluation of target lesions before enrollment was used as baseline tumor evaluation.
One month after the last TACE, all subjects underwent plain CT and enhanced MRI examinations, which were compared with the baseline of target lesions.
The efficacy was evaluated according to the mRECIST (Modified Response Evaluation Criteria in Solid Tumors)for the treatment of solid tumors in target foci.
For example, multiple tumor foci were embolized at the same time, and the two largest target foci were selected as the evaluation foci:
|
1 month after the last TACE -mRECIST evaluation
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSP-V-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Liver Cancer
-
University of HawaiiGlaxoSmithKlineRecruitingAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Liver CancerUnited States
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdvanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | Stage A Adult Primary Liver Cancer (BCLC) | Stage B Adult Primary Liver Cancer (BCLC)United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
Genoscience PharmaNot yet recruiting
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | Stage I Adult Primary Liver Cancer | Stage II Adult Primary Liver Cancer | Stage IIIA Adult Primary Liver Cancer
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Recruiting
Clinical Trials on Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug
-
Washington University School of MedicineRecruitingChronic Subdural HematomaUnited States
-
Zhongda HospitalNot yet recruitingColorectal Cancer Liver Metastasis
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital... and other collaboratorsRecruitingHepatocellular Carcinoma, AdultChina
-
Karolinska InstitutetRecruiting
-
Kecioren Education and Training HospitalCompletedEpistaxis | Tranexamic Acid | Nasal PackingTurkey
-
University of WashingtonGuerbetWithdrawnMalignant Neoplasm in the Head and Neck | Metastatic Malignant Neoplasm in the Head and NeckUnited States
-
Sun Yat-sen UniversityFirst People's Hospital of Foshan; Guangzhou No.12 People's HospitalCompleted
-
University of British ColumbiaCompleted
-
Sun Yat-sen UniversityCompletedHepatocellular CarcinomaChina
-
Sun Yat-sen UniversityGuangzhou No.12 People's Hospital; Kaiping Central HospitalWithdrawnHepatocellular CarcinomaChina